

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/250097 A1

(51) International Patent Classification:

C07K 16/08 (2006.01) *A61P 31/20* (2006.01)
A61P 13/12 (2006.01) *A61P 37/06* (2006.01)
A61P 31/12 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2021/065462

(22) International Filing Date:

09 June 2021 (09.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20179041.7 09 June 2020 (09.06.2020) EP
20179044.1 09 June 2020 (09.06.2020) EP

(71) Applicants: **MEMO THERAPEUTICS AG** [CH/CH];
Wagistrasse 27, 8952 Schlieren (CH). **UNIVERSITÄT
BERN** [CH/CH]; Verwaltungsdirektion, Hochschulstrasse
6, 3012 Bern (CH). **UNIVERSITÄT ZÜRICH** [CH/CH];
Prorektorat Forschung, Rämistrasse 71, 8006 Zürich (CH).

(72) Inventors: **WEBER, Marcel**; Dammstrasse 54, 8037
Zürich (CH). **SCHMITT, Simone**; Zürcherstrasse 80,
8953 Dietikon (CH). **ESSLINGER, Christoph**; Witikon-
strasse 70, 8032 Zürich (CH). **SCHACHTNER, Thomas**;
Rennweg 15, 8001 Zürich (CH). **HUYNH-DO, Uyen**;
Könizstrasse 194H, 3097 Liebefeld (CH). **PROVEN-
ZANO, Maurizio**; Zelgli 7, 5708 Birrwil (CH).

(74) Agent: **BÜHLER, Dirk**; Maiwald Patentanwalts- Und
Rechtsanwaltsgesellschaft MbH, Elisenhof, Elisenstraße 3,
80335 München (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTI-BK VIRUS ANTIBODY MOLECULES

(57) Abstract: Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.

WO 2021/250097 A1